Surgery Partners/$SGRY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Surgery Partners
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
- Ticker
- $SGRY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16,000
- Headquarters
- Brentwood, United States
- Website
- www.surgerypartners.com
Surgery Partners Metrics
BasicAdvanced
$2B
-
-$0.69
1.92
-
Price and volume
Market cap
$2B
Beta
1.92
52-week high
$23.44
52-week low
$11.41
Average daily volume
2.1M
Financial strength
Current ratio
1.946
Quick ratio
1.44
Long term debt to equity
1.131
Total debt to equity
1.082
Interest coverage (TTM)
1.60%
Profitability
EBITDA (TTM)
646.4
Gross margin (TTM)
22.51%
Net profit margin (TTM)
-2.63%
Operating margin (TTM)
13.94%
Effective tax rate (TTM)
20.02%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
3.66%
Return on equity (TTM)
2.32%
Valuation
Price to revenue (TTM)
0.605
Price to book
1.2
Price to tangible book (TTM)
1.2
Price to free cash flow (TTM)
10.858
Free cash flow yield (TTM)
9.21%
Free cash flow per share (TTM)
1.464
Growth
Revenue change (TTM)
3.99%
Earnings per share change (TTM)
-51.56%
3-year revenue growth (CAGR)
8.15%
10-year revenue growth (CAGR)
12.48%
3-year earnings per share growth (CAGR)
11.79%
10-year earnings per share growth (CAGR)
14.11%
What the Analysts think about Surgery Partners
Analyst ratings (Buy, Hold, Sell) for Surgery Partners stock.
Analyst projections of the future price of Surgery Partners stock.
Bulls say / Bears say
Second-quarter same-facility revenue rose 5.0%, with revenue per case up 4.8%; this points to continued growth in the core business, although case volumes were nearly flat. (Surgery Partners Inc.)
The Idaho Falls sale brought in $587 million of net cash proceeds and shifts the company towards a more focused short-stay surgery business. The proceeds should strengthen the balance sheet, while exiting broader hospital services simplifies the portfolio. (Surgery Partners Inc.)
Physician recruitment and new centres offer a route to faster growth: 330 physicians joined in the first half, while six facilities were under construction and seven more were in the pipeline at the second-quarter update. (The Motley Fool)
Profitability weakened despite higher revenue: second-quarter adjusted EBITDA fell 2.9% year on year and the net loss attributable to Surgery Partners widened to $15 million from $2.5 million. (Surgery Partners Inc.)
Debt and financing costs remain a significant drag: total debt was $3.75 billion at June-end, while first-half net interest expense rose to $138.9 million from $130.1 million a year earlier. Operating cash flow also fell year on year, to $71 million from $87.3 million. (SEC)
Underlying case growth was weak, with same-facility cases up only 0.3% in the quarter, while private insurance fell to 48.6% of patient revenue from 52.1% a year earlier. That leaves growth more reliant on higher revenue per case and a payer mix with a larger government share. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Surgery Partners Financial Performance
Revenues and expenses
Surgery Partners Earnings Performance
Company profitability
Upcoming events
No upcoming events
Surgery Partners News
AllArticlesVideos
Funds containing Surgery Partners
AllUSDEURGBP
Fund name | Fund size | $SGRY weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.03% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.